Francesco Massari

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Immunohistochemical characterization of somatically derived “yolk sac tumors”: analysis of a multi-institutional case series

  Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2026-06-18

• Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study

  European Urology Oncology · 2026-06-01

• Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study

  Minerva Urology and Nephrology · 2026-06-01

• Reproducible Human Reward Imaging Phenotypes Exhibit Differential Sensitivity to Dopamine D2 Receptor Antagonism

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-05-16

• Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics

  Targeted Oncology · 2026-05-01

• An agent-based learning model integrating sex differences in renal cell carcinoma

  Frontiers in Immunology · 2026-04-01

• Role of Local Treatment to the Prostate in Patients With de Novo Low-volume Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors

  European Urology Open Science · 2026-03-30

• Registro PONTE-SC/SCA: ottimizzazione della terapia medica negli ambulatori pugliesi per i pazienti con scompenso cardiaco

  Giornale italiano di cardiologia · 2026-03-25

• PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an “EMBARK-Like” cohort

  Prostate Cancer and Prostatic Diseases · 2026-02-25

• Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

  Frontiers in Immunology · 2026-02-24 · 1 citations

• New insights into Nectin-4 expression in testicular choriocarcinoma and its potential treatment with Enfortumab Vedotin: analysis of a multi-institutional series and association with clinical-pathological features

  Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 2026-01-21 · 1 citations

• Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

  Prostate Cancer and Prostatic Diseases · 2026-01-08 · 3 citations

• Belzutifan monotherapy and combination therapies in renal cell carcinoma: a clinical trial perspective from the ARON working group

  Expert Opinion on Pharmacotherapy · 2026-01-02 · 2 citations

• Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2EV project

  Clinical and Experimental Medicine · 2025-12-29 · 2 citations

• Reply to: Comments on “Toxicity‐related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune‐based combinations ( <scp>ARON</scp> ‐1 study)”

  International Journal of Cancer · 2025-12-16

• Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years?

  Expert Opinion on Investigational Drugs · 2025-12-02

• Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis

  Drug Design Development and Therapy · 2025-12-01 · 9 citations

• Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study

  Clinical & Experimental Metastasis · 2025-11-21

• Congestion and systemic inflammation in acute heart failure: correlations and prognostic role

  Frontiers in Cardiovascular Medicine · 2025-11-17 · 1 citations

• Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

  Cancer Immunology Immunotherapy · 2025-11-14 · 6 citations